MX2020008086A - Metodos y composiciones para tratar la apnea del sue?o. - Google Patents
Metodos y composiciones para tratar la apnea del sue?o.Info
- Publication number
- MX2020008086A MX2020008086A MX2020008086A MX2020008086A MX2020008086A MX 2020008086 A MX2020008086 A MX 2020008086A MX 2020008086 A MX2020008086 A MX 2020008086A MX 2020008086 A MX2020008086 A MX 2020008086A MX 2020008086 A MX2020008086 A MX 2020008086A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- sleep apnea
- compositions
- treating sleep
- nri
- Prior art date
Links
- 201000002859 sleep apnea Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 abstract 5
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 abstract 5
- XIQVNETUBQGFHX-QFIPXVFZSA-N (R)-oxybutynin Chemical compound C1([C@](O)(C(=O)OCC#CCN(CC)CC)C=2C=CC=CC=2)CCCCC1 XIQVNETUBQGFHX-QFIPXVFZSA-N 0.000 abstract 2
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 abstract 1
- 229960002430 atomoxetine Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En general, la invención se refiere a composiciones farmacéuticas que comprenden (R)-oxibutinina y un inhibidor de la recaptación de la norepinefrina (IRN), y a métodos para tratar la apnea del sueño que comprenden administrar (R)-oxibutinina y un inhibidor de la recaptación de la norepinefrina (IRN). En algunas realizaciones, el IRN es atomoxetina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862623892P | 2018-01-30 | 2018-01-30 | |
| PCT/US2019/015781 WO2019152475A1 (en) | 2018-01-30 | 2019-01-30 | Methods and compositions for treating sleep apnea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008086A true MX2020008086A (es) | 2021-02-15 |
Family
ID=65441079
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008086A MX2020008086A (es) | 2018-01-30 | 2019-01-30 | Metodos y composiciones para tratar la apnea del sue?o. |
| MX2024001713A MX2024001713A (es) | 2018-01-30 | 2020-07-30 | Metodos y composiciones para tratar la apnea del sue?o. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001713A MX2024001713A (es) | 2018-01-30 | 2020-07-30 | Metodos y composiciones para tratar la apnea del sue?o. |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US11911351B2 (es) |
| EP (2) | EP3746126B1 (es) |
| JP (3) | JP7422666B2 (es) |
| KR (2) | KR20250156197A (es) |
| CN (2) | CN118384147A (es) |
| AU (2) | AU2019214891B2 (es) |
| BR (1) | BR112020015316A2 (es) |
| CA (1) | CA3089712A1 (es) |
| DK (1) | DK3746126T3 (es) |
| EA (1) | EA202091597A1 (es) |
| ES (1) | ES2991425T3 (es) |
| FI (1) | FI3746126T3 (es) |
| HR (1) | HRP20241412T1 (es) |
| HU (1) | HUE068505T2 (es) |
| IL (1) | IL276247A (es) |
| LT (1) | LT3746126T (es) |
| MA (1) | MA52861B1 (es) |
| MD (1) | MD3746126T2 (es) |
| MX (2) | MX2020008086A (es) |
| PL (1) | PL3746126T3 (es) |
| PT (1) | PT3746126T (es) |
| RS (1) | RS66104B1 (es) |
| SG (1) | SG11202007226UA (es) |
| SI (1) | SI3746126T1 (es) |
| SM (1) | SMT202400400T1 (es) |
| UA (1) | UA129618C2 (es) |
| WO (1) | WO2019152475A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018260666B2 (en) | 2017-04-28 | 2022-07-21 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treating sleep apnea |
| EP4635514A3 (en) | 2019-02-08 | 2025-12-24 | The Brigham & Women's Hospital, Inc. | Methods and compositions for treating sleep apnea |
| WO2021091902A1 (en) * | 2019-11-04 | 2021-05-14 | Apnimed, Inc. (Delaware) | Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea |
| CN116391233A (zh) * | 2020-09-30 | 2023-07-04 | 皇家飞利浦有限公司 | 用于执行剂量滴定的方法和系统 |
| WO2022187420A1 (en) * | 2021-03-04 | 2022-09-09 | Apnimed, Inc. (Delaware) | Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea |
| GEAP202416361A (en) * | 2021-03-24 | 2024-04-25 | Apnimed Inc Delaware | Methods and compositions for treating sleep apnea |
| WO2022235726A1 (en) | 2021-05-04 | 2022-11-10 | Apnimed, Inc. (Delaware) | Solid forms of (r)-oxybutynin d-malate |
| KR20240021920A (ko) * | 2021-06-17 | 2024-02-19 | 애프니메드, 인코포레이티드 (델라웨어) | 수면 무호흡증을 치료하기 위한 노르에피네프린 재흡수 억제제 |
| US20250049779A1 (en) | 2021-12-22 | 2025-02-13 | Bayer Aktiengesellschaft | Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea |
| MX2024007767A (es) | 2021-12-22 | 2024-07-04 | Bayer Ag | Combinacion de un antagonista del adrenoceptor a2 subtipo c (alfa-2c) con un antagonista del receptor muscarinico para el tratamiento de la apnea del sue?o. |
| US20250302814A1 (en) * | 2022-05-13 | 2025-10-02 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| KR20250000641A (ko) * | 2023-06-27 | 2025-01-03 | 주식회사 아스트로젠 | 수면장애 및/또는 수면장애 관련 질환을 예방, 개선 또는 치료하는 방법 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL267508A (es) | 1960-07-26 | |||
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| ES2268712T3 (es) | 1995-10-24 | 2007-03-16 | Grunenthal Gmbh | Montirelina para inhibir la apnea del sueño. |
| PT1257277E (pt) | 2000-02-24 | 2005-09-30 | Pharmacia & Upjohn Co Llc | Novas combinacoes de farmacos |
| US20020155113A1 (en) | 2001-03-13 | 2002-10-24 | Miyoung Chun | Methods for treating or preventing cardiovascular disorders by modulating metalloprotease function |
| US20030060513A1 (en) | 2001-09-27 | 2003-03-27 | Arneric Stephen P. | Pharmaceutical composition |
| US20030185882A1 (en) | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
| US20040235925A1 (en) | 2002-12-17 | 2004-11-25 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| US20050009862A1 (en) | 2003-04-25 | 2005-01-13 | Sabounjian Luann | Method for promoting uninterrupted sleep by administration of trospium chloride |
| SG133606A1 (en) | 2003-12-22 | 2007-07-30 | Acadia Pharm Inc | Amino substituted diaryl [a,d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| US20060039867A1 (en) | 2004-08-20 | 2006-02-23 | Cypress Bioscience, Inc. | Method for treating sleep-related breathing disorders with setiptiline |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| WO2006055854A2 (en) | 2004-11-17 | 2006-05-26 | Cypress Bioscience, Inc. | Methods for reducing the side effects associated with mirtazapine treatment |
| KR20070087678A (ko) | 2004-12-20 | 2007-08-28 | 컬리지움 파마슈티칼, 인코포레이티드 | 수면 장애용 약제 조성물 |
| CA2646729A1 (en) | 2005-03-21 | 2006-09-28 | Dov Pharmaceutical, Inc. | Methods and compositions for the treatment of urinary incontinence |
| CA2603920A1 (en) | 2005-04-15 | 2006-10-26 | The Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
| US20070021322A1 (en) | 2005-07-21 | 2007-01-25 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Selective resonance of chemical structures |
| FR2889811B1 (fr) | 2005-08-19 | 2009-10-09 | Sanofi Aventis Sa | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique. |
| ES2610508T3 (es) | 2006-11-22 | 2017-04-27 | Clinical Research Associates, Llc | Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo |
| WO2008122019A1 (en) | 2007-04-02 | 2008-10-09 | Cypress Biosciences, Inc. | Improving the tolerability of both mirtazapine and reboxetine by using them in combination |
| EP2455076A1 (en) | 2007-04-09 | 2012-05-23 | Sepracor Inc. | Compositions comprising desvenlafaxine for use in treating sleep-related breathing disorders |
| US8415390B2 (en) | 2008-05-30 | 2013-04-09 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| US20090048233A1 (en) | 2007-08-16 | 2009-02-19 | Cypress Biosciences, Inc. | Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination |
| CN101925349A (zh) | 2007-12-21 | 2010-12-22 | 欧兰德股份有限公司 | 替马西泮的口腔崩解片组合物 |
| US20100204058A1 (en) | 2009-01-28 | 2010-08-12 | Howard Yuan-Hao Chang | Profiling for Determination of Response to Treatment for Inflammatory Disease |
| CN102939008A (zh) | 2010-04-01 | 2013-02-20 | 塞拉维达公司 | 改善睡眠质量的方法 |
| CA2825309C (en) | 2011-01-28 | 2019-10-01 | Pfantastic Medical Research Institute, Llc | Pyridostigmine for the treatment of obstructive sleep apnea |
| JP2012176958A (ja) | 2012-04-20 | 2012-09-13 | Watson Pharmaceuticals Inc | （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置 |
| US20160008334A1 (en) | 2013-03-05 | 2016-01-14 | Requis Pharmaceuticals Inc. | Preparations for the Treatment of Sleep-Related Respiratory Disorders |
| WO2016062279A1 (zh) | 2014-10-24 | 2016-04-28 | 朗齐生物医学股份有限公司 | 苹果酸丙氯陪拉辛锭用于制备治疗癌症药物的用途 |
| DK3288946T3 (da) | 2015-04-27 | 2019-11-25 | Arena Pharm Inc | 5-ht2c-receptoragonister og sammensætninger og anvendelsesfremgangsmåder |
| ES2925951T3 (es) | 2015-07-22 | 2022-10-20 | John Hsu | Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso |
| US20180235934A1 (en) | 2015-08-18 | 2018-08-23 | Massachusetts Institute Of Technology | Noradrenergic drug treatment of obstructive sleep apnea |
| AU2018260666B2 (en) * | 2017-04-28 | 2022-07-21 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treating sleep apnea |
| MX2020007876A (es) | 2018-01-31 | 2020-12-03 | Res Inst Nationwide Childrens Hospital | Terapia genica para la distrofia muscular de cinturas tipo 2c. |
| EP4635514A3 (en) | 2019-02-08 | 2025-12-24 | The Brigham & Women's Hospital, Inc. | Methods and compositions for treating sleep apnea |
-
2019
- 2019-01-30 EP EP19705634.4A patent/EP3746126B1/en active Active
- 2019-01-30 HU HUE19705634A patent/HUE068505T2/hu unknown
- 2019-01-30 SG SG11202007226UA patent/SG11202007226UA/en unknown
- 2019-01-30 US US16/965,960 patent/US11911351B2/en active Active
- 2019-01-30 ES ES19705634T patent/ES2991425T3/es active Active
- 2019-01-30 EP EP24183712.9A patent/EP4445951A3/en active Pending
- 2019-01-30 PT PT197056344T patent/PT3746126T/pt unknown
- 2019-01-30 SI SI201930847T patent/SI3746126T1/sl unknown
- 2019-01-30 FI FIEP19705634.4T patent/FI3746126T3/fi active
- 2019-01-30 PL PL19705634.4T patent/PL3746126T3/pl unknown
- 2019-01-30 JP JP2020542075A patent/JP7422666B2/ja active Active
- 2019-01-30 KR KR1020257034519A patent/KR20250156197A/ko active Pending
- 2019-01-30 HR HRP20241412TT patent/HRP20241412T1/hr unknown
- 2019-01-30 EA EA202091597A patent/EA202091597A1/ru unknown
- 2019-01-30 DK DK19705634.4T patent/DK3746126T3/da active
- 2019-01-30 UA UAA202004819A patent/UA129618C2/uk unknown
- 2019-01-30 LT LTEPPCT/US2019/015781T patent/LT3746126T/lt unknown
- 2019-01-30 CN CN202410467832.8A patent/CN118384147A/zh active Pending
- 2019-01-30 KR KR1020207024790A patent/KR102874891B1/ko active Active
- 2019-01-30 MD MDE20201230T patent/MD3746126T2/ro unknown
- 2019-01-30 MX MX2020008086A patent/MX2020008086A/es unknown
- 2019-01-30 CA CA3089712A patent/CA3089712A1/en active Pending
- 2019-01-30 WO PCT/US2019/015781 patent/WO2019152475A1/en not_active Ceased
- 2019-01-30 AU AU2019214891A patent/AU2019214891B2/en active Active
- 2019-01-30 SM SM20240400T patent/SMT202400400T1/it unknown
- 2019-01-30 BR BR112020015316-8A patent/BR112020015316A2/pt unknown
- 2019-01-30 RS RS20241137A patent/RS66104B1/sr unknown
- 2019-01-30 CN CN201980010884.XA patent/CN111670050A/zh active Pending
- 2019-01-30 MA MA52861A patent/MA52861B1/fr unknown
-
2020
- 2020-07-23 IL IL276247A patent/IL276247A/en unknown
- 2020-07-30 MX MX2024001713A patent/MX2024001713A/es unknown
-
2022
- 2022-08-05 US US17/882,318 patent/US20220378724A1/en not_active Abandoned
-
2023
- 2023-10-25 JP JP2023183525A patent/JP2023181322A/ja active Pending
-
2024
- 2024-01-23 US US18/419,974 patent/US20240156753A1/en not_active Abandoned
- 2024-08-06 US US18/795,245 patent/US20240390299A1/en not_active Abandoned
- 2024-10-25 AU AU2024227631A patent/AU2024227631A1/en active Pending
-
2025
- 2025-02-17 US US19/055,172 patent/US20250186371A1/en not_active Abandoned
- 2025-08-22 JP JP2025138640A patent/JP2025159230A/ja active Pending
- 2025-10-02 US US19/348,331 patent/US20260027070A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024001713A (es) | Metodos y composiciones para tratar la apnea del sue?o. | |
| GEAP202316320A (en) | Methods and compositions for treating sleep apnea | |
| MX2022013612A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. | |
| MX2015012760A (es) | Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma. | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| TN2013000239A1 (en) | New form of administration of enkephalinase inhibitor | |
| AR092993A1 (es) | Laquinimod para reducir el daño talamico en la esclerosis multiple | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| BR112016013754A2 (pt) | Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma | |
| EP4635514A3 (en) | Methods and compositions for treating sleep apnea | |
| EP4582141A3 (en) | Oral composition for the treatment of gastroesophageal reflux and laryngopharyngeal reflux | |
| MX2022007113A (es) | Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas. | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| MX2022005813A (es) | Formas de dosificacion novedosas de rofecoxib y métodos relacionados. | |
| EP4591928A3 (en) | Composition for the treatment of gastroesophageal reflux comprising hyaluronic acid | |
| EA201892098A1 (ru) | Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения | |
| AU2018258588A8 (en) | Inhibitors of TRIM33 and methods of use | |
| GR1008228B (el) | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου | |
| MX2023014709A (es) | Inhibidores de la recaptacion de norepinefrina para tratamiento de la apnea del sue?o. | |
| CL2023002824A1 (es) | Métodos y composiciones para tratar la apnea del sueño | |
| IN2013MU03428A (es) | ||
| EA201170874A1 (ru) | Новое применение фибратов | |
| HK40109751A (en) | Norepinephrine reuptake inhibitors for treating sleep apnea | |
| MX2021008887A (es) | Minociclina para el tratamiento del sindrome de pitt-hopkins. |